-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34

Benzinga·08/07/2026 23:37:04
Listen to the news
UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.